Cloudreach and AWS Sign Strategic Collaboration Agreement to Accelerate Global Cloud Adoption
Cloudreach, a leading independent cloud services provider, and Amazon Web Services (AWS), today unveiled a new Strategic Collaboration Agreement. The wide-ranging agreement will mean an acceleration of the companies’ joint go-to-market proposition, along with investments in Cloudreach software innovation, geographical expansion and the launch of a Talent Academy.
This agreement builds on the well-established 12-year relationship between Cloudreach and AWS. Cloudreach will expand within North America and Europe including into new territories Canada, Poland, Spain and the Nordics. In addition, Cloudreach will make significant investments in software, further developing its SMART Migration™ and SMART Modernization™ services. These services are designed to accelerate enterprise cloud adoption through intelligent automation and will help more customers to realize the benefits of AWS services with far greater efficiency.
Cloudreach CEO, Brooks Borcherding, said: “After 12 years of collaboration with AWS, we’re excited to be entering this new phase of growth. Together, we’re focused on delivering the promise of the cloud through new software-driven capabilities coupled with industry-best practices and expertise. For our customers this will mean adopting AWS cloud more efficiently and with greater confidence, achieving a faster time to value.”
Launch of Cloudreach Talent Academy
A key initiative within the agreement is the launch of a Talent Academy. The Academy is designed to train hundreds of diverse and promising candidates to become the next generation of cloud professionals. For entry into the program, Cloudreach will look for candidates with a passion for building their career in cloud, even if they do not have a technical background, and fast-track their technical development.
The program will bring more talent into the AWS community, offering candidates a path to acquire and upskill their AWS capabilities. The Talent Academy is unique in its emphasis on recruiting from a diverse pool of candidates who traditionally have not selected technical career paths. Cloudreach expects hundreds of candidates to become AWS-certified and get the hands-on experience to become cloud consultants, engineers, architects, and developers.
“Cloudreach is committed to addressing underrepresentation and the lack of diversity within the technology workforce and cloud industry. This purpose-driven investment is one of the most exciting aspects of this collaboration with AWS. We’re dedicated to be helping future professionals develop their careers where they will solve complex business challenges for our joint customers,” added Borcherding.
Doug Yeum, Head of Worldwide Channels and Alliances at AWS, said: “We are delighted to build upon the 12-year relationship with AWS Premier Partner, Cloudreach. This collaboration means AWS can bring the highest level of cloud native expertise to an even wider audience with Cloudreach, significantly accelerating the pace of global cloud adoption. We are also particularly appreciative of Cloudreach’s focus on expanding the diverse talent pool of AWS-skilled professionals, which aligns with our leadership principles as a company.”
This engagement will provide AWS and Cloudreach customers with compelling new SMART Migration™ and SMART Modernization™ service offerings to dramatically accelerate cloud adoption and reduce time-to-value by 40%. These new offerings leverage both Cloudamize, a leading planning, assessment, and migration automation software, and Sunstone, a cloud modernization machine learning engine to make continuous modernization recommendations for legacy and cloud deployed services.
Marie Measures, Chief Technology Officer at Sanne Group, the alternative asset fund administrator, said: “The possibilities are endless when you engage with an AWS Partner that’s flexible, easy to work with, and shares your organization’s values. We want to move quickly along our cloud journey and, thanks to Cloudreach and AWS, we have a well-structured transformational roadmap.”
For more details about the collaboration between AWS and Cloudreach, please visit: www.cloudreach.com/en/partners/aws-premier-consulting-partner/
– ENDS –
About Cloudreach
Cloudreach is the world’s leading independent cloud services company. Our mission is to deliver the promise of cloud and drive extraordinary value for our customers. Cloudreach helps enterprises win competitive advantage through successful cloud transformation. With more than 10 years of cloud native experience, we’ve built an unmatched depth and breadth of expertise in cloud technologies and their application to business. For more information about our work, visit www.cloudreach.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005334/en/
Contact information
Press Contact
Rahim Hakimi
Email: rahim.hakimi@cloudreach.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom